### COVID-19 OUTPATIENT TREATMENT GUIDELINES ROADMAP

#### Risk Factors for severe COVID-19

- Advanced age
- Male sex
- Presence of chronic medical conditions
- Obesity
- Sacral trauma

#### When providing products under Emergency Use Authorization, providers must:

2. Ensure patient understands the risks and benefits of the product.
3. Obtain informed consent.
4. Discuss alternatives with patient.
5. Document discussion and consent in the medical record.

#### Options depicted in gray should be considered after other options, if other options are unavailable, or only in certain clinical situations.

#### Management of Patients with COVID-19

**Does your patient have COVID?**

1. Is your patient hospitalized for COVID-19 or requiring isolation? NO
2. Is medical attention delayed due to COVID-19? NO
3. Does your patient have any symptoms? YES
4. How many days since symptom onset? ≤ 8 DAYS

#### Dosing Instructions

- **Paxlovid™**
  - Dosing: 5 mg/kg IV on day 1, followed by 5 mg/kg IV on days 2-3
  - Weight ≥ 40 kg
  - ≥ 60 mL/min

- **Remdesivir (Veklury®)**
  - Dosing: 250 mL high-titer neutralizing antibody in 5% dextrose, 30 min to <60 mL/min

- **Evusheld™**
  - Dosing: 200 mg/kg IV in patients who weigh ≥ 40 kg or ≥ 60 mL/min

#### References

1. COVID-19 Treatment Guidelines (nih.gov)
2. Management of Patients with COVID-19 (idsociety.org)
3. COVID-19 Outpatient Treatment Roadmap (cdc.gov)
4. CDC List of Medical Conditions with risk of progression to severe COVID-19 (cdc.gov)
5. University of Liverpool COVID-19 Drug Interactions (unliverpool.ac.uk)
6. FDA Emergency Use Authorization (fda.gov)
7. IDSA guidance on outpatient use of convalescent plasma (idsociety.org)
8. COVID-19 Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma (cdcss.org)

---


[Image of the flowchart]